“It’s crazy this stuff, it’s burning through our bodies,” said a man who encountered the animal tranquilizer xylazine in the drugs he used.
Ultragenyx has found early success with its experimental treatment for the rare disease Angelman syndrome.
Hospital and health insurance pricing data surfaced by new federal transparency rules are creating an opportunity for startups to help patients fight exorbitant medical bills.
A WHO advisory committee outlined a new set of definitions that more accurately reflect the science of airborne disease transmission.
Second-generation mosquito nets prevented 13 million malaria cases and 25,000 deaths in large pilot programs.
Comparisons to seasonal flu management underestimate the unique challenges posed by H5N1 bird flu.
A new analysis of health inequities shows that every state has deep racial and ethnic disparities in the performance of their health care systems.
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Millions of children are coming of age in an unrestricted and unprotected digital universe. They need guardrails that can keep them safe.
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess…
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
